Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Annual Meeting Talks
2024
What Do the HARBOR Data Reveal About the Relationship Between the Drying of Subretinal and Intraretinal Fluid and Associated Vision Outcomes?
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2019

Category: AMD-Neovascular

See more